Geranylgeranyl Diphosphate Synthase Inhibitor and Proteasome Inhibitor Combination Therapy in Multiple Myeloma
نویسندگان
چکیده
منابع مشابه
Proteasome inhibitor therapy in multiple myeloma.
Multiple myeloma remains incurable despite available therapies, and novel therapies that target both tumor cell and bone marrow microenvironment are urgently needed. Preclinical in vitro and in vivo studies show remarkable anti-multiple myeloma activity of the proteasome inhibitor bortezomib/PS-341 even in multiple myeloma cells refractory to multiple prior therapies, including dexamethasone, m...
متن کاملBortezomib / proteasome inhibitor PS - 341 resistance in multiple myeloma
198 words; Text4628 words Blood First Edition Paper, prepublished online June 24, 2004; DOI 10.1182/blood-2004-02-0547 Copyright (c) 2004 American Society of Hematology only. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From
متن کاملGerfelin, a novel inhibitor of geranylgeranyl diphosphate synthase from Beauveria felina QN22047. II. Structural elucidation.
Sir: Protein geranylgeranylation of small GTP-binding proteins, such as Rho, Rac, Cdc42 and Rab1), is essential for the function of the modified proteins. Protein geranylgeranylation is a key target for chemotherapeutic intervention in a number of diseases. Because geranylgeranyl diphosphate synthase (GGPP synthase)2,3) is involved in a pathway for protein geranylgeranylation, we screened an in...
متن کاملCarfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Although the incidence of multiple myeloma (MM) is increasing, the median overall survival and the number of agents in the pipeline for treating MM also are increasing. Response rates higher than 80% are not uncommon in the frontline setting when the novel agents thalidomide, lenalidomide, and bortezomib are used in combination. Response rates and survival also have improved in disease that has...
متن کاملXPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
Acquired proteasome-inhibitor (PI) resistance is a major obstacle in the treatment of multiple myeloma (MM). We investigated whether the clinical XPO1-inhibitor selinexor, when combined with bortezomib or carfilzomib, could overcome acquired resistance in MM. PI-resistant myeloma cell lines both in vitro and in vivo and refractory myeloma patient biopsies were treated with selinexor/bortezomib ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2019
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2019-129244